Immunotherapy for Prostate Cancer: Where We Are Headed
AbstractProstate cancer is one of the most common malignant neoplasms in men worldwide, and is the fifth cause of cancer-related death. In recent years, a new generation of therapies have been approved for the management of metastatic disease. Moreover, the development of new immunotherapeutic drugs has become a novel frontier for the treatment of several tumor types; to date, numerous studies have investigated their potential activity, including in prostate cancer. In this article, we discuss the role of emerging immunotherapeutic drugs in prostate cancer patients. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Schepisi, G.; Farolfi, A.; Conteduca, V.; Martignano, F.; De Lisi, D.; Ravaglia, G.; Rossi, L.; Menna, C.; Bellia, S.R.; Barone, D.; Gunelli, R.; De Giorgi, U. Immunotherapy for Prostate Cancer: Where We Are Headed. Int. J. Mol. Sci. 2017, 18, 2627.
Schepisi G, Farolfi A, Conteduca V, Martignano F, De Lisi D, Ravaglia G, Rossi L, Menna C, Bellia SR, Barone D, Gunelli R, De Giorgi U. Immunotherapy for Prostate Cancer: Where We Are Headed. International Journal of Molecular Sciences. 2017; 18(12):2627.Chicago/Turabian Style
Schepisi, Giuseppe; Farolfi, Alberto; Conteduca, Vincenza; Martignano, Filippo; De Lisi, Delia; Ravaglia, Giorgia; Rossi, Lorena; Menna, Cecilia; Bellia, Salvatore R.; Barone, Domenico; Gunelli, Roberta; De Giorgi, Ugo. 2017. "Immunotherapy for Prostate Cancer: Where We Are Headed." Int. J. Mol. Sci. 18, no. 12: 2627.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.